4basebio (LON:4BB) Releases Earnings Results

4basebio (LON:4BB) released its quarterly earnings data on Monday. The company reported GBX (0.57) EPS for the quarter, Digital Look Earnings reports.

4basebio Trading Down 0.5%

LON 4BB traded down GBX 2.70 during trading on Wednesday, hitting GBX 559.80. 115 shares of the company’s stock traded hands, compared to its average volume of 1,346. The stock has a fifty day moving average of GBX 512.25 and a two-hundred day moving average of GBX 510.12. 4basebio has a 12-month low of GBX 420 and a 12-month high of GBX 820. The firm has a market cap of £86.69 million, a P/E ratio of -5.14 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52.

Analysts Set New Price Targets

Separately, Royal Bank Of Canada lowered their price objective on shares of 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a research report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of GBX 1,400.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.